FOENIX-CCA2: A Phase 2, Open-label, Multicenter Study of Futibatinib in Patients With Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements

Lipika Goyal,1 Funda Meric-Bernstam,2 Antoine Hollebecque,3 Juan W. Valle,4,5 Chigusa Morizane,6 Thomas B. Karasic,7 Thomas A. Abrams,8 Junji Furuse,9 Helen He,10 Nital Soni,10 Karim A. Benhadji,10 John A. Bridgewater11

Lipika Goyal, MD

Massachusetts General Hospital,
Boston, Massachusetts, USA

1Massachusetts General Hospital, Boston, Massachusetts, USA; 2University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Drug Development, Institut Gustave Roussy, Villejuif, France; 4University of Manchester, Manchester, UK; 5The Christie NHS Foundation Trust, Manchester, UK; 6National Cancer Center Hospital, Tokyo, Japan; 7Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 8Dana-Farber Cancer Institute, Boston, MA, USA; 9Kyorin University, Faculty of Medicine, Tokyo, Japan; 10Taiho Oncology, Inc., Princeton, NJ, USA; 11UCL Cancer Institute, London, UK


New York, NY, USA